Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7471954 | 0.98 | SIGMAR1 (0.47) | SIGMAR1METAP1ADRA2CGNAO1RAD52 | |
| SCHEMBL11214645 | 0.76 | — | — | |
| SCHEMBL28970037 | 0.75 | SLC6A4 (0.32) | — | |
| SCHEMBL2116575 | 0.71 | SIGMAR1 (0.36) | SIGMAR1GNAO1 | |
| SCHEMBL991079 | 0.69 | SLC6A4 (0.31) | — | |
| SCHEMBL6413142 | 0.69 | SIGMAR1 (0.36) | SIGMAR1GNAO1 | |
| SCHEMBL542927 | 0.68 | SIGMAR1 (0.43) | SIGMAR1GNAO1 | |
| SCHEMBL2052871 | 0.68 | MEN1 (0.34) | — | |
| SCHEMBL11181437 | 0.67 | RAD52 (0.52) | SIGMAR1ADRA2CGNAO1RAD52 | |
| SCHEMBL7957882 | 0.67 | CYP1A2 (0.44) | SIGMAR1METAP1GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6479482-B2 | 4-(3-((((3-(4-((3-METHYLBUTYL)AMINO)-1-PIPERIDINYL)PROPYL) -AMINO)-CARBONYL)AMINO)PHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5 -PYRIDINEDICARBOXYLIC ACID, DIMETHYL ESTER DIHYDROCHLORIDE, FOR EXAMPLE; ANOREXIANT; NEUROPEPTIDE Y (NPY) | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-12 | — | — | US | disclosed |
| US-20020019384-A1 | Alkylamine derivatives of dihydropyridine NPY antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-14 | — | — | US | disclosed |
| WO-2001085173-A1 | ALKYLAMINE DERIVATIVES OF DIHYDROPYRIDINE NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019384-A1 | Alkylamine derivatives of dihydropyridine NPY antagonists | NPY1R, NPY2R, NPY4R | SIGMAR1 108/4885METAP1 1292/4885ADRA2C 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.